Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Shares started out the week mixed in Asia after U.S. stocks fell to their worst loss since Election Day. Japan’s Nikkei 225 index dropped 1% to 38,255.65 as the yen regained some strength against the ...

Moderna reported phase 3 results with its vaccine last month. Meanwhile, for CureVac, the deal provides a much-needed cash injection, coming alongside an announcement that it will slash its ...

See your plan by selecting location, age, and other applicable factors Sign up to be alerted when there are vaccination updates in your state: The Plan Your Vaccine page will be updated as new ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

Donald Trump has chosen vaccine sceptic Robert F Kennedy Jr as his new health secretary and said he will do "unbelievable things". The news was announced by Donald Trump Jr on X, before the ...

The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.

Why the iPhone SE 4 Could Be One of Apple's Most Important Products of 2025 ...